Well-differentiated villoglandular adenocarcinoma of the uterine cervix: Oncogene/tumor suppressor gene alterations and human papillomavirus genotyping

International Journal of Gynecological Pathology

Volumn 19, Issue 2, 2000, Pages 110-117

  Jones, Mirka W ^a   Kounelis, Sophia ^a   Papadaki, Helen ^a   Bakker, Anke ^b   Swalsky, Patricia A ^b   Woods, Jeffrey ^b   Finkelstein, Sydney D ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cervix; HPV; Oncogene; Tumor suppressor gene; Well differentiated villoglandular adenocarcinoma

Indexed keywords

ADULT; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE LOSS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WART VIRUS;

EID: 0034000943     PISSN: 02771691     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004347-200004000-00003     Document Type: Article

References (43)

1. Wright TC, Ferenczy A, Kurman RJ. Carcinoma and other tumors of the cervix. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract. New York: Springer-Verlag, 1994:279-309.
2. Ferguson A, Svoboda-Newman SM, Frank TS. Analysis of human papillomavirus infection and molecular alterations in adenocarcinoma of the cervix. Mod Pathol 1998;11:11-8.
3. Nielsen AL. Human papillomavirus type 16/18 in uterine cervical adenocarcinoma in situ and adenocarcinoma. Cancer 1990;65: 2588-93.
4. Duggan MA, McGregor SE, Benoit JI, Masafumi I, Nation JG, Stuart GCE. The human papillomavirus status of invasive cervical adenocarcinoma: a clinicopathological and outcome analysis. Hum Pathol 1995;26;319-25.
5. Tase T, Okagaki T, Clark B, et al. Human papillomavirus types and localization in adenocarcinoma and adenosquamous carcinoma of the uterine cervix: a study by in situ DNA hybridization. Cancer Res 1988;48:993-8.
6. Wells M, Lane S. Human papillomaviruses, p53, and cervical neoplasia. J Pathol 1994;172:299-300.
7. Cooper K, Herrington CS, Lo ES, Evans MF, McGee JO. Integration of human papillomavirus types 16 and 18 in cervical adenocarcinoma. J Clin Pathol 1992;45:382-4.
8. Greenblatt MS, Bennet WP, Hollstein M, Harris CC. Mutations in p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4885-78.
9. Friedman LS, Ostermeyer EA, Szabo CI, Dowd P, Lynch ED, Rowell SE, King MC. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994;8:399-404.
10. Briscoe WT, Ray DB, Airhart JL, et al. A new high frequency polymorphism in the HER-2/neu oncogene in normal tissue and breast tumors. Breast Cancer Res Treat 1993;28:45-9.
11. Meyers SL, Dudley JP. Sequence analysis of the int-2/fgf-3 gene in aggressive human breast carcinomas. Mol Carcinogen 1992;6: 243-51.
12. Kounelis S, Jones MW, Papadaki H, Bakker A, Swalsky PA, Finkelstein SD. Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum Pathol 1998;29: 82-7.
13. Caduff RF, Johnston CM, Frank TS. Mutations of Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 1995;146:182-8.
14. Sasaki H, Nishii H, Takahashi H, et al. Mutation of the Ki-ras proto-oncogene in human endometrial hyperplasia and carcinoma. Cancer Res 1993;53:1906-10.
15. Medhl M, Sevelda P, Czerwenka K, et al. DNA amplification of Her-2/neu and INT-2 oncogenes in epithelial ovarian cancer. Gynecol Oncol 1995;59:321-6.
16. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
17. Hamilton SR. Molecular genetics of colorectal carcinoma. Cancer 1992;70:1216-21.
18. Finkelstein SD, Przygodzki RM, Pricolo VE, et al. Prediction of biological aggressiveness in colorectal cancer by p53/K-ras-2 topographic genotyping. Mol Diagn 1996;1:5-28.
19. Finkelstein SD, Sayegh R, Christensen S, Swalsky P. Genotypic classification of colorectal adenocarcinoma correlates with biological behavior. Cancer 1993;71:3827-38.
20. Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD, Goeddel DV. Activation of K-ras-2 gene human colon and lung carcinomas by two different point mutations. Nature 1983;304:507-13.
21. Peltomaki P, Sistonen P, Mecklin JP, et al. Evidence that the MCC-APC gene region in 5q21 is not the site for susceptibility to hereditary nonpolyposis colorectal carcinoma. Cancer Res 1992; 52:4530-3.
22. Heighway J, Hoban PR, Wyllie AH. Ssp1 polymorphism in sequence encoding 3′ untranslated region of the APC gene [Abstract]. Nucleic Acids Res 1991;19:6966.
23. Heighway J, Hoban PR, Wyllie AH. MaeIII polymorphism in sequence encoding 3′ untranslated region of the MCC gene [Abstract]. Nucleic Acids Res 1992;20;1160.
24. Young RH, Scully RE. Villoglandular papillary adenocarcinoma of the uterine cervix: a clinicopathologic analysis of 13 cases. Cancer 1989;63;1773-9.
25. Jones MW, Silverberg SG, Kurman RJ. Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a climcopathological study of 24 cases. Int J Gynecol Pathol 1993;12:1-7.
26. Lungu O, Wright Jr TC, Silverstein S. Typing of human papillomavirus by polymerase chain reaction amplification with L1 consensus primers and RFLP analysis. Mol Cell Probes 1992;6:145-52.
27. Finkelstein S, Przygodzki RM, Swalsy PA. Microdissection-based P53 genotyping: recommendations for molecular testing. Mol Diag 1999, in press.
28. Hahn M, Fislage R, Pingouol A. Polymorphism of the pentanucleotide repeat d(AAAAT) within intron of the human tumor suppressor gene p-53 (17p13.1). Hum Genet 1994;93:222.
29. McDaniel T, Carbone D, Takahashi T, et al. The Msp1 polymorphism in intron 6 of p53 (TP53) detected by digestion of PCR products [Abstract]. Nucleic Acids Res 1991;19:4796.
30. Dressen JC, Bras M, Coonen E, Dumoulin JC, Evers JL, Geraedts JP. Allelic dropout caused by allele-specific amplification failure in single-cell PCR of the cystic fibrosis delta F508 deletion. J Assist Reprod Genet 1996;13:112-4.
31. Rechitsky S, Freidine M, Verlinsky Y, Strom CM. Allele dropout in sequential PCR and FISH analysis of single cells (cell recycling). J Assist Reprod Genet 1996;13:115-24.
32. Czernobilsky B, Kessler I, Lancet M. Cervical carcinoma in a woman on long-term contraceptives. Obstet Gynecol 1974;43: 517-21.
33. Michael H, Sutton G, Hull MT, Roth LM. Villous adenoma of the uterine cervix associated with invasive adenocarcinoma: a histologic, ultrastructural and immunohistochemical study. Int J Gynecol Pathol 1986;5:163-9.
34. Liang XH, Volkman M, Klein R, Herman B, Lockett SJ. Colocalization of the tumor-suppressor protein p53 and human papillomavirus E6 protein in human cervical carcinoma cell lines. Oncogene 1993;8:2645-52.
35. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 248:76-9.
36. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63:1129-36.
37. Crook T, Tidy J, Vousden KH. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and transactionation. Cell 1991;67:547-56.
38. Fugita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res 1992;52: 5323-8.
39. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus-negative tumors. Lancet 1992;339:1070-3.
40. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991;6: 873-5.
41. Riou G, Favre M, Jeannel D, Bourhis J, LeDoussal V, Orth G. Association between poor prognosis in early-stage invasive cervical carcinoma and non-detection of HPV DNA. Lancet 1990;335: 1171-4.
42. Higgins GD, Davy M, Roder D, Uzelin DM, Philips GE, Burrell GJ. Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 1991;338: 910-3.
43. Mandai M, Konishi I, Koshiyama M, et al. Altered expression of nm23-H1 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. Cancer 1995;75:23-9.